(Total Views: 665)
Posted On: 02/19/2025 1:06:57 PM
Post# of 150746
I was just talking about this yesterday...
"Investigators reported that patients who received leronlimab (n = 30) experienced a 400% to 660% increase in mean PFS (mPFS)/PFS and 12-month PFS, as well as a 570% to 980% increase in 12-month mOS/OS. Additionally, a 73% decrease in circulating tumor cells was observed in this patient population."
where are the follow up studies!
"Investigators reported that patients who received leronlimab (n = 30) experienced a 400% to 660% increase in mean PFS (mPFS)/PFS and 12-month PFS, as well as a 570% to 980% increase in 12-month mOS/OS. Additionally, a 73% decrease in circulating tumor cells was observed in this patient population."
where are the follow up studies!
(3)
(0)Scroll down for more posts ▼
